Q-Suite® Holmium-166 SIRT treatment planning software receives CE-mark approval

DEVENTER, Jun. 8 2020 – Quirem Medical announced today it received CE-mark approval for the latest version of Q-Suite®, dosimetry software for holmium-166 SIRT. Q-Suite® is the only dosimetry software solution tailored to treatment planning and treatment evaluation of Holmium-166 Selective Internal Radiation Therapy (SIRT). In combination with the work-up product QuiremScout® and treatment product QuiremSpheres®, the software solution facilitates improved patient selection and treatment planning to further optimize SIRT outcomes.

The new CE-mark for Q-Suite® adds SIRT treatment planning functionality to the already available treatment evaluation features. Founder and CEO of Quirem Medical, Jan Sigger comments: “The treatment planning functionality in Q-Suite completes our integrated holmium-SIRT solution, built around QuiremSpheres®, QuiremScout® and Q-Suite®. This integrated solution will give physicians the tools to further personalize SIRT towards the individual needs of each patient”

Treatment planning with Q-Suite® includes calculation of the required QuiremSpheres® treatment activity, prediction of lung dose based on a QuiremScout® or Tc-99m MAA pre-scan and performing a pre-treatment dose simulation. Treatment evaluation with Q-Suite® allows for dosimetry after QuiremSpheres® SIRT using MR or SPECT-CT images.

Gerrit van de Maat, software development lead at Quirem Medical comments: “Q-Suite® leverages the unique imaging properties of holmium-166 microspheres for treatment planning and evaluation. We are pleased that we could include planning functionality to support physicians during the holmium-166 SIRT work-up phase. While extending the functionality, we ensured that Q-Suite® remains simple and intuitive to use in daily clinical practice.

 

About Quirem Medical B.V.

Quirem Medical is an emerging medical device company with a mission to develop the next generation microspheres for selective internal radiotherapy (SIRT) of liver malignancies. Quirem Medical BV is a spin-off company of the University Medical Center Utrecht (UMCU) and commercializes, manufactures and distributes a new type of SIRT microspheres based on the isotope holmium, named QuiremSpheres®. QuiremSpheres® and QuiremScout® have received CE-mark approval in April 2015 and December 2018 respectively and are currently being used by numerous centers in Europe and Turkey.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on email

Necessary cookies help make a website more usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

Enable

Statistical cookies help us understand how visitors use the website by collecting and reporting data anonymously. These cookies therefore do not collect any personal data from visitors.

Cookies are small text files that can be used by websites to make user experiences more efficient. By law, we may store cookies on your device if they are strictly necessary for the use of the website. These are the functional cookies. We need your consent for all other types of cookies. These cookies are named as: preferences and statistics and you do not have to accept them. This website uses different types of cookies. Some cookies are placed by third party services that are displayed on our pages.

This website uses cookies to improve your experience. You can manage your options here.